- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Review of TA879.
- Process:
- STA Standard
- ID number:
- 6680
Provisional Schedule
- Committee meeting: 1:
- 03 November 2026
- Expected publication:
- 13 January 2027
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Daiichi Sankyo (trastuzumab deruxtecan)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- None
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Amarox (irinotecan) (confidentiality agreement not signed, not participating)
- Bristol Myers Squibb (paclitaxel) (confidentiality agreement not signed, not participating)
- Genus Pharmaceuticals (paclitaxel) (confidentiality agreement not signed, not participating)
- Hospira (docetaxel, irinotecan, paclitaxel) (confidentiality agreement not signed, not participating)
- Medac pharma (irinotecan) (confidentiality agreement not signed, not participating)
- Pfizer (irinotecan) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (docetaxel, irinotecan, paclitaxel) (confidentiality agreement not signed, not participating)
- Servier Laboratories (irinotecan, trifluridine–tipiracil) (confidentiality agreement not signed, not participating)
- Sun Pharma (irinotecan) (confidentiality agreement not signed, not participating)
- Teva UK (paclitaxel) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 April 2026 | Invitation to participate |
| 19 February 2026 - 16 March 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 16 February 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 16 February 2026 | In progress. Draft scope consultation issued. |
For further information on our processes and methods, please see our CHTE processes and methods manual